In rheumatoid arthritis patients treated for 12 months with tocilizumab, an anti-interleukin-6 receptor monoclonal antibody that rapidly reduces acute phase reactants, C3 and C4 serum levels also decrease [68]. The gene discussed is C4A; the disease is rheumatoid arthritis.